News and Announcements
Insync’s Global Equity Funds deliver +30% returns in 2019
- Published December 16, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Our four key pillars for business success are now in place – Product, Process, People and Performance.
Key highlights in building the business foundation in 2019 included:
⦁ For 12 months to 30th November 2019 our Funds returned:
⦁ 33.84% in the Global Quality Equity Fund and
⦁ 32.59% in the Global Capital Aware Fund
⦁ Reached $50+ million Funds under Management – Year on Year increase of +35%
⦁ Passed 10 years of operation with top quartile performance against comparable funds in each time period – 1, 3, 5 and 10 years
Insync Summary Performance Report
In 2020 Insync is offering two fantastic investment opportunities for you to join us in our journey:
Take a stake in our business at a very special entry price of $10/share and reap the benefits of business growth in an industry providing significant scale opportunity with:
⦁ Industry growth at 3x global GDP.
⦁ Legislated super adding contributions at the rate of A$100bn+ per year to the A$3 trillion superannuation asset base.
⦁ Forecasted annualized profit per share to increase to $16+ by 2025.
⦁ Forecasted share value to exceed $100 per share by 2025 at a valuation rate of 10 x average earnings (before tax)
Invest in an Insync Fund and participate in its future performance with access to our:
⦁ Processes – significant IP
⦁ Products – unique solutions with competitive advantage and
⦁ People – world class experience
About Insync Funds Management Pty Ltd
Insync Funds Management Pty Ltd is a Sydney-based specialist future focused global equity funds management company established in 2009 that invests in a concentrated portfolio of highly profitable global stocks that have delivered superior returns for our fund investors over a sustained period of 10 years.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
